Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2025Human Vaccines & ImmunotherapeuticsOpen Access

Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

MJMingwei JiangJZJinrong ZhaoJYJinguo Yuan

Discussion

Loading...

Member takes

Overview

Research outlines the effectiveness of CAR T cell therapy on autoimmune diseases, suggesting new therapeutic pathways and safety profiles.

Key Points

  • Chimeric antigen receptor (CAR) T cell therapy shows long-term remission potential without drugs in autoimmune diseases.
  • Early clinical trials demonstrate promising efficacy and safety of CAR natural killer cell therapy.
  • The transition of chimeric autoantigen receptor T cell therapy from research to clinical trials marks a significant advancement.
  • Continued research aims to enhance the efficiency and safety of CAR-based immunotherapy for broader autoimmune disease applications.

Cite This Study

Jiang et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d00aahttps://doi.org/10.1080/21645515.2025.2538350
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up2024 · 1,055 citations